Natera Cancer Test Infringes Invitae Patent, Suit Alleges
Law360 (May 10, 2021, 8:01 PM EDT) -- Invitae, a genetic testing company based in San Francisco, has launched a lawsuit in Delaware federal court claiming that a non-invasive cancer detection test produced by rival Natera infringes an Invitae-owned DNA sequencing patent.
In a complaint filed Friday, Invitae Corp. said Natera Inc., based in Austin, Texas, was infringing U.S. Patent No. 10,604,799, which Invitae obtained earlier this year by way of an assignment agreement.
Specifically, the complaint said Natera's Signatera cancer diagnostic test is the infringing product. According to Natera, the test is a tumor DNA test that determines the level of cancer left in a patient.
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!